C-reactive protein: A surrogate risk marker or mediator of atherothrombosis?

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 285, Issue 5 54-5, 2003, Pages

  Blake, Gavin J ^a   Ridker, Paul M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSIGLITAZONE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INFLAMMATION; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOSIS;

EID: 0142126886     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00227.2003     Document Type: Review

References (30)

1. Albert M, Danielson E, Rifai N, and Ridker PM. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286: 64-70, 2001.
2. Blake GJ, Dada N, Fox JC, Manson JE, and Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38: 1302-1306, 2001.
3. Blake GJ and Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 89: 763-771, 2001.
4. Blake GJ, Ridker PM, and Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med 114: 485-494, 2003.
5. Blake GJ, Ridker PM, and Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 40: 49-55, 2002.
6. Devaraj S, Xu DY, and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107: 398-404, 2003.
7. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, and Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106: 679-684, 2002.
8. Heeschen C, Hamm CW, Bruemmer J, and Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 35: 1535-1542, 2000.
9. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, and Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31: 1460-1465, 1998.
10. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, and Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47: 444-450, 2001.
11. Pasceri V, Chang J, Willerson JT, and Yeh ET. Modulation of c-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534, 2001.
12. Pasceri V, Willerson JT, and Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168, 2000.
13. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, and Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511, 2003.
14. Pradhan AD, Manson JE, Rifai N, Buring JE, and Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001.
15. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363-369, 2003.
16. Ridker PM, Buring JE, Cook NR, and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 15,218 initially healthy American women. Circulation 107: 391-397, 2003.
17. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, and Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979, 1997.
18. Ridker PM, Hennekens CH, Buring JE, and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843, 2000.
19. Ridker PM, Rifai N, Clearfield M, Downs JR, Weiss SE, Miles JS, and Gotto AM. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-1965, 2001.
20. Ridker PM, Rifai N, Pfeffer MA, Sacks F, and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235, 1999.
21. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, and Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839-844, 1998.
22. Ridker PM, Rifai N, Rose L, Buring JE, and Cook NR. Comparison of C-reactive protein and LDL cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002.
23. Ridker PM, Stampfer MJ, and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285: 2481-2485, 2001.
24. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126, 1999.
25. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, and Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18: 1386-1392, 1998.
26. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106: 1439-1441, 2002.
27. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, and Mickel DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105: 1890-1896, 2002.
28. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, and Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919, 2002.
29. Yasojima K, Schwab C, McGeer EG, and McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158: 1039-1051, 2001.
30. Zwaka TP, Hombach V, and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103: 1194-1197, 2001.